the New England Section of the American Urological Association the New England Section of the American Urological Association
Search Meeting Site Only
Annual Meeting Home
Preliminary Program
Allied Health Program
Past & Future Meetings
 

Back to Annual Meeting Program


Overall Survival Benefit with Sipuleucel-T by Baseline PSA: Exploratory Analysis from the IMPACT Trial
Philip W. Kantoff, MD1, Gerald Chodak, MD2, Paul Schellhammer, MD3, James B. Whitmore, PhD4, Robert B. Sims, MD4.
1Dana-Farber Cancer Institute of Harvard Medical School, Boston, MA, USA, 2Louis A Weiss Memorial Hospital, Chicago, IL, USA, 3Eastern Virginia Medical School / Urology of Virginia, Norfolk, VA, USA, 4Dendreon, Seattle, WA, USA.

BACKGROUND: : In the IMPACT trial, sipuleucel−T reduced risk of death by 22.5% (P=0.032). A pre−specified subgroup analysis for baseline prognostic variables showed homogeneous treatment effects consistently favoring sipuleucel−T. In patients with baseline PSA below vs above the median, there was a trend toward greater treatment effect (HR=0.685 vs. 0.865). In this exploratory analysis, we further sub−divided baseline PSA into quartiles to evaluate potential treatment effect patterns.
METHODS: All randomized IMPACT patients (n=512) were categorized by baseline PSA quartile, ECOG, and other prognostic variables (LDH, PAP, ALP in bone−only disease, Hgb). Median overall survival (OS) and hazard ratio (HR) were estimated using Kaplan−Meier and Cox models, respectively.
RESULTS: Increasing baseline PSA quartile was associated with markers of advanced disease. Although there was inadequate power to demonstrate inter−quartile significance, data suggest a consistent treatment effect in all subsets and a trend toward an increased effect with lower baseline PSA. A similar benefit was suggested for other prognostic variables, with the exception of baseline Hgb.
CONCLUSIONS: This analysis supports a consistent OS benefit with sipuleucel−T across PSA quartiles, and suggests that patients with less advanced disease may benefit more from treatment with sipuleucel−T.


Back to Annual Meeting Program

 


© 2018 New England Section of the American Urological Association. All Rights Reserved. Privacy Policy.